I build and scale healthcare companies at the point where exceptional science meets commercial reality—so better technology can reach more patients.
Rob Lozuk is a biotechnology executive with more than two decades of experience commercializing disruptive technologies across diagnostics and life sciences. He is founder and CEO of ZEN Diagnostics, through which he holds several board roles. He has led global commercial organizations, built operating teams, and helped guide healthcare companies through pivotal transactions. He holds a degree from UC Santa Barbara.
His work is grounded in a straightforward belief: the best science only changes lives when teams can translate it into accessible, scalable products.
Leading an early cancer detection company developing blood-based tests built on mRNA and the body’s immune response. Led multiple financing rounds to advance the platform and its path to commercialization.
Advising and building emerging diagnostics businesses at critical moments of strategy, scale, and commercialization.
Helped advance a biosignal platform through the company’s acquisition by Paragraf in 2023.
Scaled Specific Diagnostics as President through its sale to bioMérieux in 2022.
Led global commercial operations at Sequenom and held P&L, sales, marketing, and business development roles at Thermo Fisher Scientific.
These board roles are held through ZEN Diagnostics.
A breakthrough diagnostic is the beginning, not the finish line. The work is building the evidence, teams, commercial systems, and trust that move great science out of the lab and into routine care—where earlier answers can change what happens next.
Syantra’s blood-based platform uses mRNA biomarkers and machine learning to detect changes in the body associated with cancer. The company’s Onco-ID Breast test is designed to complement existing screening where important gaps remain.
Led multiple financing rounds to support Syantra’s growth and commercialization.
Read the Syantra announcementThe amount of blood described by Syantra for measuring its biomarker expression profile.
For board, speaking, media, and industry inquiries, reach Rob directly by email.
For background on Syantra, its AI-powered RNA platform, and Onco-ID Breast.
View media background